CIDP market seen reaching $3.32 billion by 2030
The global chronic inflammatory demyelinating polyneuropathy market is projected to rise from $2.27 billion in 2025 to $2.46 billion in 2026, with growth driven by broader diagnosis, IVIG access and more specialized neurology care. The Business Research Company says the market could reach $3.32 billion by 2030 as targeted immunotherapies, remote monitoring and home-based treatment expand.
Why it matters: - CIDP is a rare autoimmune disease that damages peripheral nerves, causing weakness, numbness and balance problems. - Market growth points to more diagnosis, more treatment options and higher demand for long-term disease management. - Expanding spending on healthcare can improve access to therapies and earlier intervention for patients with rare neuropathies.
What happened: - The Business Research Company published its Chronic Inflammatory Demyelinating Polyneuropathy Global Market Report 2026 on the CIDP market. - The report estimates the market will grow from $2.27 billion in 2025 to $2.46 billion in 2026, an 8.1% CAGR. - The report projects the market will reach $3.32 billion by 2030, implying a 7.8% CAGR from 2026 to 2030. - North America held the largest CIDP market share in 2025. - The report also covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa.
The details: - The 2026 growth reflects wider awareness of rare autoimmune neuropathies. - Better access to intravenous immunoglobulin, or IVIG, is supporting demand. - Improved electrodiagnostic testing is helping identify CIDP and its subtypes. - More specialized neurology care is expanding treatment access. - The report says future growth will be driven by targeted immunotherapies, efforts to reduce treatment side effects, remote patient monitoring, sustained-remission therapies and more rare-disease research funding. - Expected trends include wider first-line use of IVIG, more personalized treatment protocols, advanced diagnostics, more home-based treatment and stronger long-term disease management. - The report links rising healthcare expenditure to market growth because higher spending can support infrastructure, insurance coverage and access to advanced therapies. - The UK Office for National Statistics reported a 5.6% nominal rise in total healthcare expenditure from 2022 to 2023, compared with 0.9% the year before. - The company also promoted new report features, including market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspot infographics, and updated graphics and tables. - The report offers a free sample and the full report through the company’s website. - Download the free sample - View the full report
Between the lines: - The report suggests CIDP is moving from a narrowly managed rare disease toward a more data-driven and personalized treatment market. - The emphasis on home-based care and remote monitoring signals pressure to reduce the burden of chronic therapy for patients and providers. - North America’s lead suggests the region has stronger diagnostic capacity, treatment access and commercial adoption than other markets.
What's next: - The CIDP market is expected to keep expanding through 2030 as more patients are diagnosed earlier and treated with newer therapies. - Adoption of home-based treatment and remote monitoring could reshape how CIDP care is delivered. - Research investment in rare diseases may support more targeted drugs and longer-lasting remission options. - Market reports for 2026 will continue to add forecasting tools and analytics features aimed at investors and healthcare companies.
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
Middle East News Journal
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.